title: Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories.
abstract: BACKGROUND
  Hemolytic transfusion reactions due to platelet transfusions containing ABO-incompatible plasma (ie, group O platelets into a non-group O patient) have been reported in the literature. However, limited data describe the extent to which transfusion services manage such platelet transfusions or the methods used to limit the risk of such reactions.
  
  
  OBJECTIVE
  To determine transfusion services' current practices regarding the use of platelets containing ABO-incompatible plasma.
  
  
  METHODS
  In a College of American Pathologists' Transfusion Medicine Proficiency Testing Survey, supplemental questions asked participants whether a policy existed for the use of platelets containing ABO-incompatible plasma and, if a policy existed, what elements were part of the policy.
  
  
  RESULTS
  Of 3156 laboratories that transfused platelets, 3152 responded to the question of whether they had a policy. Of these respondents, 83% (n = 2623) had a policy. One or more elements were reported for transfusions in adults: only ABO-compatible plasma products (n = 1363); only ABO-compatible plasma and platelet products (n = 679); notification of medical director (n = 646); notification of ordering physician (n = 637); volume limit of ABO-incompatible plasma allowed (n = 255); volume-reduction of ABO-incompatible products (n = 168); screening for critical titer of anti-A or anti-B (n = 53). A total of 529 laboratories indicated that they did not have a policy.
  
  
  CONCLUSIONS
  A majority of laboratories have a policy, but most do not include a method to limit the risk of hemolysis if platelets containing ABO-incompatible plasma must be transfused. When such platelets are used, there does not appear to be consensus on a specific method to minimize the transfusion of anti-A or anti-B.
authors.affiliation: Department of Pathology, Fletcher Allen Health Care, 111 Colchester Ave, Burlington, VT 05401, USA. mark.fung@vtmednet.org
authors.forename: Mark K
authors.initials: MK
authors.lastname: Fung
authors.forename: Katharine A
authors.initials: KA
authors.lastname: Downes
authors.forename: Ira A
authors.initials: IA
authors.lastname: Shulman
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D001771:Blood Banks / Q000592:standards*; D001787:Blood Group Incompatibility / Q000276:immunology / Q000517:prevention & control*; D001788:Blood Grouping and Crossmatching / Q000592:standards; D006461:Hemolysis; D006801:Humans; D009656:North America; D017713:Platelet Transfusion / Q000592:standards*; D011795:Surveys and Questionnaires
chemical_list: D000017:ABO Blood-Group System